Please note, this OEL/ADE monograph also applies to Hydroxychloroquine sulfate (CAS RN 747-36-4). Hydroxychloroquine is a chemotherapeutic agent indicated for treatment of malarial infection, rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE). Hydroxychloroquine is a racemic mixture. Hydroxychloroquine may act by concentrating in the malarial parasite and inhibiting heme polymerase thereby inhibiting the formation of heme. Hydroxychloroquine, like chloroquine, is a weak base and may exert an effect by concentrating in the lysosomes of the malaria parasite. This interferes with the ability of the parasite to lyse hemoglobin, preventing the normal growth and replication of the parasite.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Hydroxychloroquine, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’s OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.